191.55 -0.21 (-0.11%)
After hours: 7:28PM EDT
|Bid||191.52 x 900|
|Ask||191.77 x 800|
|Day's Range||190.29 - 192.77|
|52 Week Range||163.31 - 201.23|
|PE Ratio (TTM)||62.83|
|Earnings Date||Jul 26, 2018|
|Forward Dividend & Yield||5.28 (2.72%)|
|1y Target Est||196.10|
"Halftime Report" trader Pete Najarian and Mad Money's Jim Cramer discuss unusual options activity in Amgen and the XOP energy ETF.
THOUSAND OAKS, Calif. and LOS ANGELES, July 19, 2018 /PRNewswire/ -- Amgen (AMGN) and Cedars-Sinai Medical Center today announced a partnership to help support the improvement of healthcare quality in the treatment of multiple therapeutic areas that could include oncology, cardiovascular disease, osteoporosis and migraine. The organizations intend to jointly undertake research projects in one or more of these therapeutic areas. Proposed initial projects under the three-year agreement focus on cancer therapies, in line with Cedars-Sinai's ranking as Southern California's largest provider of oncology services and Amgen's leadership in the field.
THOUSAND OAKS, Calif., July 18, 2018 /PRNewswire/ -- Amgen (AMGN) today announced the launch of Myeloma MVPTM, a national campaign to help those affected by multiple myeloma create their Most Valuable Plan, an individualized approach for managing their disease. Multiple myeloma is an incurable blood cancer for which there are a variety of treatment options, requiring patients to work closely with their doctors to determine the right plan to meet their needs.
It has been a pretty ho-hum week for the biotech sector with a few regulatory updates. Amgen resubmits BLA for osteoporosis drug and Advaxis surges on positive news from FDA.
FDA approves Pfizer's (PFE) sNDA to expand the label of Xtandi to include the non-metastatic prostate cancer patient population.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting AMGN. Over the last one-month, outflows of investor capital in ETFs holding AMGN totaled $140 million.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 12) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Arbutus Biopharma ...
THOUSAND OAKS, Calif. and BRUSSELS, July 12, 2018 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced the resubmission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for EVENITY™* (romosozumab), an investigational monoclonal antibody for the treatment of osteoporosis in postmenopausal women at high risk for fracture. EVENITY increases bone formation and reduces bone resorption simultaneously to increase bone mineral density (BMD) and reduce the risk of fracture. "A fracture due to osteoporosis can be a life-altering event, and EVENITY has the potential to reduce fracture risk in patients at high risk due to a prior fracture," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.
As the economy reaches the later stages of its cycle and profit growth slows, investors should take a look at Goldman Sachs’ basket of more than 30 Russell 1000 stocks with high gross profit margins that have proven stable over time. Seven of those stocks, which have been recent outperformers, include Verisign Inc. ( VRSN), Amgen Inc. ( AMGN), Cadence Design Systems Inc. ( CDNS), Adobe Systems Inc. ( ADBE), IDEXX Laboratories Inc. ( IDXX), Liberty Media Corp. ( LSXMA) and O’Reilly Automotive Inc. ( ORLY).
This could indicate that investors who seek to profit from falling equity prices are not currently targeting AMGN. Over the last one-month, outflows of investor capital in ETFs holding AMGN totaled $820 million.
According to Incyte Corporation (INCY), the firm is a “Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics.”
Shares of Amgen also moved north as Wall Street's celebration of Biogen's news pushed many biotech stocks higher. Biogen Inc. shares were jumping on Friday, closing the day up almost 20% on high volume compared to usual. The company along with Eisai Co. Ltd. of Japan had announced positive results from an Alzheimer's study.
Several major biotech stocks rallied on Friday after Biogen (BIIB) reported positive results from a Phase 2 study of its Ban2401 therapy, which seeks to reduce toxic amyloid proteins associated with cognitive decline and Alzheimer's disease.
The NASDAQ Biotechnology Index rose about 3% in midday trading Friday to 3,636.45, the highest level since February. underperforming the overall NASDAQ Index in the past year, investors might be recognizing the hidden value of the firms' drug research and development, says Steve Chesney, an analyst for Atlantic Equities in London who covers large cap biotech firms worth more than $60 billion. Celgene, a biotechnology company which develops anti-inflammatory drugs for cancer and other diseases rose around 2% to $82.09 in early afternoon trading.
In this daily bar chart of AMGN, below, we can see a number of bullish developments. The daily On-Balance-Volume (OBV) line shows an uptrend from November signaling more aggressive buying for months. In this weekly bar chart of AMGN, below, we can see an uptrend from late 2016.